KR20230066095A - 항-b7h4 항체-약물 접합체 요법에 대한 점수산정 방법 - Google Patents

항-b7h4 항체-약물 접합체 요법에 대한 점수산정 방법 Download PDF

Info

Publication number
KR20230066095A
KR20230066095A KR1020237012322A KR20237012322A KR20230066095A KR 20230066095 A KR20230066095 A KR 20230066095A KR 1020237012322 A KR1020237012322 A KR 1020237012322A KR 20237012322 A KR20237012322 A KR 20237012322A KR 20230066095 A KR20230066095 A KR 20230066095A
Authority
KR
South Korea
Prior art keywords
adc
cancer
cell
antibody
seq
Prior art date
Application number
KR1020237012322A
Other languages
English (en)
Korean (ko)
Inventor
귄터 쉬미트
니콜라스 브리우
안드레아스 스피츠뮐러
안쉬 카필
체 헹 탄
필립 보르트만
Original Assignee
메디뮨 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 리미티드 filed Critical 메디뮨 리미티드
Publication of KR20230066095A publication Critical patent/KR20230066095A/ko

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F18/00—Pattern recognition
    • G06F18/20—Analysing
    • G06F18/22—Matching criteria, e.g. proximity measures
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F18/00—Pattern recognition
    • G06F18/20—Analysing
    • G06F18/24—Classification techniques
    • G06F18/241—Classification techniques relating to the classification model, e.g. parametric or non-parametric approaches
    • G06F18/2413—Classification techniques relating to the classification model, e.g. parametric or non-parametric approaches based on distances to training or reference patterns
    • G06F18/24133—Distances to prototypes
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F18/00—Pattern recognition
    • G06F18/20—Analysing
    • G06F18/25—Fusion techniques
    • G06F18/254—Fusion techniques of classification results, e.g. of results related to same input data
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V10/00—Arrangements for image or video recognition or understanding
    • G06V10/40—Extraction of image or video features
    • G06V10/44—Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersections; Connectivity analysis, e.g. of connected components
    • G06V10/443—Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersections; Connectivity analysis, e.g. of connected components by matching or filtering
    • G06V10/449—Biologically inspired filters, e.g. difference of Gaussians [DoG] or Gabor filters
    • G06V10/451—Biologically inspired filters, e.g. difference of Gaussians [DoG] or Gabor filters with interaction between the filter responses, e.g. cortical complex cells
    • G06V10/454—Integrating the filters into a hierarchical structure, e.g. convolutional neural networks [CNN]
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V20/00—Scenes; Scene-specific elements
    • G06V20/60—Type of objects
    • G06V20/69—Microscopic objects, e.g. biological cells or cellular parts
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V20/00—Scenes; Scene-specific elements
    • G06V20/60—Type of objects
    • G06V20/69—Microscopic objects, e.g. biological cells or cellular parts
    • G06V20/695—Preprocessing, e.g. image segmentation
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V20/00—Scenes; Scene-specific elements
    • G06V20/60—Type of objects
    • G06V20/69—Microscopic objects, e.g. biological cells or cellular parts
    • G06V20/698—Matching; Classification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V2201/00—Indexing scheme relating to image or video recognition or understanding
    • G06V2201/03—Recognition of patterns in medical or anatomical images

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Theoretical Computer Science (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Artificial Intelligence (AREA)
  • Evolutionary Computation (AREA)
  • Multimedia (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
KR1020237012322A 2020-09-12 2021-09-13 항-b7h4 항체-약물 접합체 요법에 대한 점수산정 방법 KR20230066095A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063077607P 2020-09-12 2020-09-12
US63/077,607 2020-09-12
PCT/EP2021/075116 WO2022053685A2 (fr) 2020-09-12 2021-09-13 Méthode de notation associée à une thérapie par conjugué anticorps-anti-b7h4-médicament

Publications (1)

Publication Number Publication Date
KR20230066095A true KR20230066095A (ko) 2023-05-12

Family

ID=77913114

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237012322A KR20230066095A (ko) 2020-09-12 2021-09-13 항-b7h4 항체-약물 접합체 요법에 대한 점수산정 방법

Country Status (8)

Country Link
EP (1) EP4211663A2 (fr)
JP (1) JP2023542301A (fr)
KR (1) KR20230066095A (fr)
CN (1) CN116615455A (fr)
AU (1) AU2021342349A1 (fr)
CA (1) CA3194182A1 (fr)
IL (1) IL301264A (fr)
WO (1) WO2022053685A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115160403A (zh) * 2022-07-05 2022-10-11 上海彩迩文生化科技有限公司 特异性拓扑异构酶抑制剂和可用于抗体药物偶联物及其制备方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE3546806C2 (fr) 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2016841C (fr) 1989-05-16 1999-09-21 William D. Huse Methode de production de polymeres ayant une activite choisie
WO1990014443A1 (fr) 1989-05-16 1990-11-29 Huse William D Coexpression de recepteurs heteromeres
CA2016842A1 (fr) 1989-05-16 1990-11-16 Richard A. Lerner Methode pour puiser dans le repertoire immunologique
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
ATE249840T1 (de) 1991-12-13 2003-10-15 Xoma Corp Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
ES2353268T3 (es) 1999-07-02 2011-02-28 Morphosys Ag Generacion de elementos de union especifica que se unen a (poli)peptidos codificados por fragmentos de adn genomico o est.
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
NZ539395A (en) 2002-11-07 2009-01-31 Immunogen Inc Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
JP5712396B2 (ja) * 2012-03-30 2015-05-07 公益財団法人神奈川科学技術アカデミー イメージングセルソーター
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
EP3108446B1 (fr) * 2014-02-21 2019-03-20 Ventana Medical Systems, Inc. Analyse d'images médicales pour l'identification de cellules tumorales positives aux marqueurs biologiques
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor
WO2019197509A1 (fr) * 2018-04-13 2019-10-17 Ventana Medical Systems, Inc. Systèmes d'estimation de forme de cellule
WO2020081343A1 (fr) * 2018-10-15 2020-04-23 Ventana Medical Systems, Inc. Systèmes et procédés de classification de cellules

Also Published As

Publication number Publication date
CN116615455A (zh) 2023-08-18
AU2021342349A1 (en) 2023-05-25
WO2022053685A3 (fr) 2022-04-21
EP4211663A2 (fr) 2023-07-19
WO2022053685A2 (fr) 2022-03-17
IL301264A (en) 2023-05-01
CA3194182A1 (fr) 2022-03-17
JP2023542301A (ja) 2023-10-06

Similar Documents

Publication Publication Date Title
KR102610592B1 (ko) 당화 pd-l1에 특이적인 항체 및 그의 사용 방법
US11046759B2 (en) Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
US8557964B2 (en) Anti CXCR4 antibodies and their use for the treatment of cancer
EP2588497B1 (fr) Nouvel anticorps destiné au diagnostic et/ou au pronostic du cancer
JP2017532025A (ja) 交差反応性ｓｉｇｌｅｃ抗体
RU2595394C2 (ru) Гуманизированные антитела к cxcr4 для лечения рака
EA039377B1 (ru) Антитела к ceacam5 и их применения
US20170029525A1 (en) Antibodies to human b7x for treatment of metastatic cancer
JP6890581B2 (ja) Ｃｄ３７の検出のための抗体およびアッセイ
JP2022511337A (ja) 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物
KR20230066095A (ko) 항-b7h4 항체-약물 접합체 요법에 대한 점수산정 방법
KR20230106607A (ko) 191p4d12 단백질에 결합하는 항체 약물 접합체(adc)로 암을 치료하는 방법
JP7485274B2 (ja) 免疫療法のためのバイオマーカーとしてのプロガストリン
RU2706967C2 (ru) Антитело к igf-1r и его применение для диагностики рака
KR20230066094A (ko) 항-her2 항체-약물 접합체 치료법을 위한 채점 방법
TWI703155B (zh) 特異性結合至ｐａｕｆ蛋白質的抗體及其用途
CN117177771A (zh) 一种诊断和治疗t细胞淋巴瘤的方法
OA19972A (en) Receptor for VISTA